STARTEEPO Invest Increases Stake in Xerox to More Than 6% Ahead of Q2 2026 Earnings
4.6.2026 13:00:00 CEST | Business Wire | Press Release
STARTEEPO Invest (“STARTEEPO”), an alternative investment fund focused on public equity opportunities, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to more than 6% of the Company’s outstanding common stock, as disclosed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission.
Following the transaction, STARTEEPO beneficially owns approximately 8.0 million Xerox common shares and holds options on an additional 140,000 shares. Based on publicly available ownership disclosures, STARTEEPO is now Xerox’s third-largest shareholder.
“We continue to view Xerox as a high-conviction investment and one of the largest positions in our portfolio,” said Frantisek Bostl, Chairman of the Board of STARTEEPO Invest. “Our conviction has increased as we continue to analyze the Company’s publicly available disclosures, strategic initiatives, and transformation efforts.”
Increasing Conviction Ahead of Q2 2026 Results
Based on our ongoing analysis of publicly available information and recent Company disclosures, STARTEEPO remains encouraged by Xerox’s operational and financial trajectory ahead of its upcoming Q2 2026 earnings release. In our view, the market may continue to underestimate the potential impact of ongoing restructuring initiatives, Lexmark integration efforts, and management’s focus on improving profitability and strengthening the Company’s balance sheet.
Accelerating Balance Sheet Transformation
STARTEEPO also believes that the recently announced warrant structure may provide Xerox with a unique opportunity to further accelerate deleveraging over time. As the Company’s share price appreciates, warrant exercises could potentially result in the issuance of new equity capital and a corresponding reduction in outstanding debt obligations. In our view, the market has not yet fully appreciated the potential long-term implications of this mechanism and its ability to improve Xerox’s capital structure.
Long-Term Opportunity in Enterprise Workflow Infrastructure
Beyond balance sheet transformation, STARTEEPO continues to develop increasing conviction regarding Xerox’s longer-term positioning within enterprise workflow automation and AI-enabled document infrastructure. As Xerox CEO Louie Pastor recently noted at the Lytham Partners Spring 2026 Conference, the Company is investing in AI-powered document workflows, intelligent document processing, content management, omnichannel communications, and IoT-enabled solutions through a dedicated business unit.
While our primary investment thesis remains centered on operational improvement, margin expansion, deleveraging, and disciplined execution, we believe the market may be overlooking a potentially significant long-term opportunity embedded within Xerox’s evolving enterprise workflow platform.
Constructive Long-Term Shareholder
STARTEEPO intends to remain a constructive long-term shareholder and may continue engaging with management, the Board of Directors, shareholders, creditors, and other market participants regarding the Company’s strategy, capital structure, operations, and opportunities to enhance long-term shareholder value.
Additional information are available at www.starteepo.com/xerox.
About STARTEEPO Invest
STARTEEPO Invest is an alternative investment fund based in Prague, Czech Republic, focused on identifying high-conviction opportunities in public equity markets. The firm applies a fundamental, long-term investment approach, with a focus on disciplined analysis and constructive engagement.
This communication expresses solely the opinion of STARTEEPO and its affiliates and not any other party. This communication is for informational purposes only and does not constitute investment advice, a recommendation, or offer to buy or sell any securities. STARTEEPO’s opinions stated herein are based on publicly available information and its own analyses. STARTEEPO may, at any time and without notice, buy, sell, reduce, increase, or otherwise change its investment position, including for reasons that may be inconsistent with the views expressed in this communication. Investing in securities involves significant risks, including the potential loss of the principal amount invested. Past performance is not a reliable indicator of future results. Every investor should conduct their own independent research and due diligence or consult with a licensed financial, legal, or tax advisor before making any investment decision.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260601535170/en/
Contacts
Media Contact
Frantisek Bostl
bostl@starteepo.com
420 604 215 002
www.starteepo.com/en -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.starteepo.c
om%2Fen&esheet=54545127&newsitemid=20260601535170&lan=en-US&anchor=www.starteepo
.com%2Fen&index=2&md5=0459bc9e5078003248cfa7d145077f75
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom